| Literature DB >> 18950149 |
Prasanta Ghorai1, Anja Kraus, Max Keller, Carsten Götte, Patrick Igel, Erich Schneider, David Schnell, Günther Bernhardt, Stefan Dove, Manfred Zabel, Sigurd Elz, Roland Seifert, Armin Buschauer.
Abstract
N1-Aryl(heteroaryl)alkyl-N2-[3-(1H-imidazol-4-yl)propyl]guanidines are potent histamine H2-receptor (H2R) agonists, but their applicability is compromised by the lack of oral bioavailability and CNS penetration. To improve pharmacokinetics, we introduced carbonyl instead of methylene adjacent to the guanidine moiety, decreasing the basicity of the novel H2R agonists by 4-5 orders of magnitude. Some acylguanidines with one phenyl ring were even more potent than their diaryl analogues. As demonstrated by HPLC-MS, the acylguanidines (bioisosteres of the alkylguanidines) were absorbed from the gut of mice and detected in brain. In GTPase assays using recombinant receptors, acylguanidines were more potent at the guinea pig than at the human H2R. At the hH1R and hH3R, the compounds were weak to moderate antagonists or partial agonists. Moreover, potent partial hH4R agonists were identified. Receptor subtype selectivity depends on the imidazolylpropylguanidine moiety (privileged structure), opening an avenue to distinct pharmacological tools including potent H4R agonists.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18950149 DOI: 10.1021/jm800841w
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446